阿立哌唑和奧氮平治療首發(fā)精神分裂癥的對比研究
發(fā)布時間：2018-09-11 06:28
【摘要】：[目的]對比分析阿立哌唑、奧氮平治療首發(fā)精神分裂癥的療效、安全性、認(rèn)知功能、經(jīng)濟(jì)負(fù)擔(dān)、社會功能和生活質(zhì)量。 [方法]40例首發(fā)精神分裂癥患者隨機(jī)分為阿立哌唑組20例和奧氮平組20例,口服阿立哌唑或奧氮平治療180天。于治療前、治療90天、治療180天評定陰性癥狀和陽性癥狀量表(PANSS)、個人和社會功能量表(PSP)、SF-36健康調(diào)查量表(SF-36),同時做藥費(fèi)調(diào)查評估成本效果評定和相關(guān)的實(shí)驗(yàn)室檢查。 [結(jié)果]1.療效方面：兩組患者在治療90天時PANSS評分總分均顯著下降(P0.05),兩組患者在治療180天時較治療90天時PANSS評分總分下降無明顯差異(P0.05)；兩組之間在治療90天時、治療180天時PANSS評分無顯著性差異(P0.05)。2.認(rèn)知功能方面：①兩組患者在治療90天時認(rèn)知功能各項(xiàng)成績(除情緒管理、符號編碼)均較治療前明顯提高(P0.05),兩組患者在治療180天時較治療90天時認(rèn)知功能各項(xiàng)成績的差異均無統(tǒng)計(jì)學(xué)意義(P0.05)。②兩組之間比較：言語學(xué)習(xí)能力方面在治療90天時、治療180天時阿立哌唑組的改善明顯高于奧氮平組(P0.05)；空間廣度方面阿立哌唑組在治療90天時順行得分和總分較治療前顯著增加(P0.05),治療180天時較治療90天時空間廣度方面的順行得分和總分均無明顯差異(P0.05),兩組在治療前后比較均無統(tǒng)計(jì)學(xué)差異(P0.05)。3.安全性方面：①阿立哌唑組在治療前后體重、空腹血糖、膽固醇及甘油三酯差異均無顯著性(P0.05),奧氮平組在治療90天時體重、空腹血糖、膽固醇及甘油三酯均顯著升高(P0.05),治療180天較治療90天時體重、空腹血糖、膽固醇及甘油三酯均無明顯差異(P0.05)。②阿立哌唑組在治療90天、治療180天時膽固醇、低密度脂蛋白水平均低于奧氮平組(P0.05)。③EPS方面兩組患者不良反應(yīng)發(fā)生率無明顯差異(P0.05)。4.經(jīng)濟(jì)負(fù)擔(dān)方面：獲得單位療效的奧氮平治療組需要256.77元,阿立哌唑治療組需要206.12元,兩組之間差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。5.社會功能及生活質(zhì)量方面：①兩組患者在治療90天、治療180天PSP總分均有顯著提高(P0.05),兩組之間無明顯差別(P0.05)。②兩組患者在治療90天、180天時SF-36各方面均有所提高,差異具有統(tǒng)計(jì)學(xué)意義(P0.05),兩組之間無明顯差別(P0.05)。 [結(jié)論]阿立哌唑組治療首發(fā)精神分裂癥患者記憶功能改善方面高于奧氮平組,對代謝方面的影響要小于奧氮平,且更高效低價。
[Abstract]:[objective] to compare the efficacy, safety, cognitive function, economic burden, social function and quality of life of aripiprazole and olanzapine in the treatment of first-episode schizophrenia. [methods] Forty patients with first-episode schizophrenia were randomly divided into aripiprazole group (n = 20) and olanzapine group (n = 20). Before treatment, 90 days after treatment, 180 days after treatment, (PANSS), personal and social function scale (PSP) SF-36 health survey scale (SF-36) was evaluated, and cost effectiveness evaluation and related laboratory tests were performed. [result] 1. Curative effect: the total scores of PANSS scores in the two groups decreased significantly at the 90th day of treatment (P0.05), and there was no significant difference between the two groups in the total scores of PANSS scores on the 180th day of treatment compared with that of the patients of the 90-day treatment group (P0.05), and between the two groups at the 90th day of treatment, There was no significant difference in PANSS score at 180 days after treatment (P0.05). Cognitive function: 1 two groups of patients in 90 days after treatment cognitive function scores (except emotional management, Symbol coding) was significantly higher than that before treatment (P0.05). There was no significant difference in cognitive performance between the two groups at 180 days after treatment and 90 days after treatment (P0.05). 2 comparison between the two groups: speech learning ability at 90 days after treatment, The improvement of aripiprazole group was significantly higher than that of olanzapine group at 180 days (P0.05). Space span of aripiprazole group at 90 days after treatment and the total score significantly increased compared with before treatment (P0.05), 180 days of treatment compared with the treatment of 90 days of space breadth of the anterograde score and total score of no significant difference (P0.05), the two groups in the treatment of space breadth of the anterograde score and total score (P0.05) There was no statistical difference before and after (P0.05). 3. There was no significant difference in body weight, fasting blood glucose, cholesterol and triglyceride between the two groups before and after treatment (P0.05), but in olanzapine group there was no significant difference in body weight, fasting blood glucose at 90 days after treatment. Cholesterol and triglyceride increased significantly (P0.05). There was no significant difference in body weight, fasting blood glucose, cholesterol and triglyceride between 180 days and 90 days after treatment (P0.05). The level of low density lipoprotein was lower than that of olanzapine group (P0.05) .3There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). 4. Economic burden: the unit efficacy of olanzapine treatment group needed 256.77 yuan, aripiprazole treatment group needed 206.12 yuan, the difference between the two groups was statistically significant (P0.05). 5. In the aspect of social function and quality of life, the total score of PSP was significantly increased in two groups after 90 days of treatment (P0.05), and there was no significant difference between the two groups (P0.05). The difference was statistically significant (P0.05), there was no significant difference between the two groups (P0.05). [conclusion] the improvement of memory function in aripiprazole group is higher than that in olanzapine group.
【學(xué)位授予單位】：昆明醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2013
【分類號】：R749.3
本文編號：2235882
[Abstract]:[objective] to compare the efficacy, safety, cognitive function, economic burden, social function and quality of life of aripiprazole and olanzapine in the treatment of first-episode schizophrenia. [methods] Forty patients with first-episode schizophrenia were randomly divided into aripiprazole group (n = 20) and olanzapine group (n = 20). Before treatment, 90 days after treatment, 180 days after treatment, (PANSS), personal and social function scale (PSP) SF-36 health survey scale (SF-36) was evaluated, and cost effectiveness evaluation and related laboratory tests were performed. [result] 1. Curative effect: the total scores of PANSS scores in the two groups decreased significantly at the 90th day of treatment (P0.05), and there was no significant difference between the two groups in the total scores of PANSS scores on the 180th day of treatment compared with that of the patients of the 90-day treatment group (P0.05), and between the two groups at the 90th day of treatment, There was no significant difference in PANSS score at 180 days after treatment (P0.05). Cognitive function: 1 two groups of patients in 90 days after treatment cognitive function scores (except emotional management, Symbol coding) was significantly higher than that before treatment (P0.05). There was no significant difference in cognitive performance between the two groups at 180 days after treatment and 90 days after treatment (P0.05). 2 comparison between the two groups: speech learning ability at 90 days after treatment, The improvement of aripiprazole group was significantly higher than that of olanzapine group at 180 days (P0.05). Space span of aripiprazole group at 90 days after treatment and the total score significantly increased compared with before treatment (P0.05), 180 days of treatment compared with the treatment of 90 days of space breadth of the anterograde score and total score of no significant difference (P0.05), the two groups in the treatment of space breadth of the anterograde score and total score (P0.05) There was no statistical difference before and after (P0.05). 3. There was no significant difference in body weight, fasting blood glucose, cholesterol and triglyceride between the two groups before and after treatment (P0.05), but in olanzapine group there was no significant difference in body weight, fasting blood glucose at 90 days after treatment. Cholesterol and triglyceride increased significantly (P0.05). There was no significant difference in body weight, fasting blood glucose, cholesterol and triglyceride between 180 days and 90 days after treatment (P0.05). The level of low density lipoprotein was lower than that of olanzapine group (P0.05) .3There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). 4. Economic burden: the unit efficacy of olanzapine treatment group needed 256.77 yuan, aripiprazole treatment group needed 206.12 yuan, the difference between the two groups was statistically significant (P0.05). 5. In the aspect of social function and quality of life, the total score of PSP was significantly increased in two groups after 90 days of treatment (P0.05), and there was no significant difference between the two groups (P0.05). The difference was statistically significant (P0.05), there was no significant difference between the two groups (P0.05). [conclusion] the improvement of memory function in aripiprazole group is higher than that in olanzapine group.
【學(xué)位授予單位】：昆明醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2013
【分類號】：R749.3
【參考文獻(xiàn)】
相關(guān)期刊論文 前5條
1 徐富玲;陳云輝;馬俊國;;奧氮平、利培酮、阿立哌唑、氯氮平引起患者心電圖異常觀察及對策[J];齊齊哈爾醫(yī)學(xué)院學(xué)報(bào);2011年02期
2 湯慶軍;;阿立哌唑與奧氮平對首發(fā)精神分裂癥患者體質(zhì)量及糖脂代謝影響的對比研究[J];精神醫(yī)學(xué)雜志;2011年05期
3 楊緒娜;朱峰;李樂華;;非典型抗精神病藥對首發(fā)精神分裂癥患者記憶功能的影響[J];中國臨床心理學(xué)雜志;2011年01期
4 曹長安;高歡;郭金宏;廖春平;樸勝斌;王鵬;梁健雄;張文順;;新型抗精神病藥物對女性精神分裂癥泌乳素、甲狀腺激素的影響[J];中國民康醫(yī)學(xué);2008年17期
5 司天梅,楊建中,舒良,王希林,孔慶梅,周沫,李雪霓,劉粹;陽性和陰性癥狀量表(PANSS,中文版)的信、效度研究[J];中國心理衛(wèi)生雜志;2004年01期
，本文編號：2235882
本文鏈接：http://sikaile.net/yixuelunwen/jsb/2235882.html
最近更新
教材專著
